Dutch Multidomain Lifestyle Intervention in Older Adults at Risk of Cognitive Decline

NCT05256199 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1210

Last updated 2025-01-07

No results posted yet for this study

Summary

FINGER-NL is a multi-center, randomized, controlled, multidomain lifestyle intervention trial among 1,206 older adults at risk for cognitive decline with a duration of 24 months. Participants are randomized in a 1:1 ratio to a personalized multi-domain lifestyle intervention (high-intensity intervention group) versus online access to general lifestyle-related health information (low-intensity intervention group). After the intervention period, participants are invited for a 24 month extension of follow-up.

Conditions

Interventions

BEHAVIORAL

Multidomain lifestyle intervention

A multidomain lifestyle intervention, including (1) physical activity, (2) cognitive training, (3) cardiovascular risk factor management (Cardiovascular), (4) dietary counselling, (5) Souvenaid, (6) sleep counselling, (7) stress management, and (8) social activities.

Sponsors & Collaborators

  • Maastricht University

    collaborator OTHER
  • Radboud University Medical Center

    collaborator OTHER
  • Wageningen University and Research

    collaborator OTHER
  • University Medical Center Groningen

    collaborator OTHER
  • Danone Nutricia Research

    collaborator INDUSTRY
  • Alzheimercentrum Amsterdam

    lead OTHER

Principal Investigators

  • Wiesje M van der Flier, Prof · Alzheimer Center Amsterdam

  • Sebastian Köhler, Ass Prof · Maastricht University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-24
Primary Completion
2025-06-01
Completion
2027-06-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05256199 on ClinicalTrials.gov